Procept Biorobotics's ROA from the second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Procept Biorobotics's ROA in the second quarter of 2026?
Procept Biorobotics Corporation recorded a cumulative net loss of $-110 million during 12 months ending in the second quarter of 2026, resulting in a negative return on assets (ROA) of -22.07%.

However, within the Healthcare sector 371 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2026 quarter, so far to 3459, from total ROA ranking in the first quarter of 2026 at 4017.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Total Assets Change	-5.98 %	-6.22 %	-2.01 %	43.46 %	43.86 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-110	-102	-96	-85	-84
Return On Assets (TTM)	-22.07 %	-20.29 %	-18.63 %	-16.4 %	-17.65 %
PRCT's Total Ranking	# 3459	# 4017	# 3465	# 3511	# 3623
Total Assets (TTM) in million	482	487	508	512	513
Seq. Total Assets Change	-0.96 %	-4.14 %	-0.68 %	-0.29 %	-1.22 %
Seq. Net Income Change	-	-	-	-	-

PRCT's 5 Years Annual ROA >> Back to PRCT Management Effectiveness >> Compare PRCT ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 120
Sector	# 372
Overall	# 3469

Return On Assets Statistics
High	Average	Low
153.6 %	-9.12 %	-35.14 %
(Dec 31 2021)		(Jun 30 2023)

Financial Statements
Procept Biorobotics's Assets	$ 482 million	PRCT's Balance sheet
Procept Biorobotics's Income	$ -27 million	Quarterly PRCT's Income Statement
PRCT's Income by Division		See PRCT's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021
Y / Y Total Assets Change	-2.01 %	34.49 %	33.97 %	-14.09 %	-
Total Assets in million	508	518	386	288	335
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-96	-91	-106	-87	-60
Annual Return On Assets	-18.81 %	-17.63 %	-27.47 %	-30.29 %	-17.87 %

PRCT's 5 Years Annual ROA >> Back to PRCT Management Effectiveness >> Compare PRCT ROA to its Competitors

More Return On Assets Ratios
PRCT's' Return on Assets at Yahoo Finance
Medical Equipment & Supplies Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
PRCT's Roa Ratio versus Medical Equipment & Supplies Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for PRCT's Competitors
Subscribers only: Roa for Procept Biorobotics's Suppliers
Subscribers only: Return On Assets for PRCT's Customers

You may also want to know
PRCT's Roi	PRCT's Inventory Turnover Ratio	PRCT's Growth Rates	PRCT's Dividend Comparisons
	PRCT's Profitability Ratios	PRCT's Asset Turnover Ratio	PRCT's Dividend Growth
PRCT's Roe	PRCT's Valuation Ratios	PRCT's Financial Strength Ratios	PRCT's Dividend Payout Ratio

Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector

ROA

Date modified: 2026-09-09T00:14:49+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.